NASDAQ:CLGN - COLLPLANT HOLDI/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.32 -0.48 (-8.28 %)
(As of 07/18/2018 12:43 PM ET)
Previous Close$5.40
Today's Range$5.32 - $5.60
52-Week Range$4.70 - $9.34
Volume300 shs
Average Volume3,124 shs
Market Capitalization$19.14 million
P/E Ratio-2.55
Dividend YieldN/A
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.

Receive CLGN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical appliances & supplies


Debt-to-Equity RatioN/A
Current Ratio3.06
Quick Ratio2.88


Trailing P/E Ratio-2.55
Forward P/E Ratio-1.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$480,000.00
Price / Sales37.91
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)($2.26)
Net Income$-6,020,000.00
Net Margins-162.90%
Return on Equity-4.47%
Return on Assets-2.25%


Outstanding Shares3,420,000
Market Cap$19.14

The Truth About Cryptocurrencies

COLLPLANT HOLDI/S (NASDAQ:CLGN) Frequently Asked Questions

What is COLLPLANT HOLDI/S's stock symbol?

COLLPLANT HOLDI/S trades on the NASDAQ under the ticker symbol "CLGN."

How were COLLPLANT HOLDI/S's earnings last quarter?

COLLPLANT HOLDI/S (NASDAQ:CLGN) issued its earnings results on Thursday, May, 24th. The company reported ($0.50) EPS for the quarter. The business earned $0.22 million during the quarter. COLLPLANT HOLDI/S had a negative net margin of 162.90% and a negative return on equity of 4.47%. View COLLPLANT HOLDI/S's Earnings History.

When is COLLPLANT HOLDI/S's next earnings date?

COLLPLANT HOLDI/S is scheduled to release their next quarterly earnings announcement on Monday, February, 11th 2019. View Earnings Estimates for COLLPLANT HOLDI/S.

What is the consensus analysts' recommendation for COLLPLANT HOLDI/S?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COLLPLANT HOLDI/S in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of COLLPLANT HOLDI/S's key competitors?

Who are COLLPLANT HOLDI/S's key executives?

COLLPLANT HOLDI/S's management team includes the folowing people:
  • Mr. Yehiel Tal, Chief Exec. Officer (Age 66)
  • Prof. Oded Shoseyov, Founder and Chief Scientist Officer (Age 62)
  • Mr. Eran Rotem, Deputy CEO & CFO (Age 50)
  • Dr. Philippe David Bensimon, VP of Regulation Affairs and Quality Assurance (Age 53)
  • Dr. Nadav Orr, VP of R&D (Age 61)


(CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

Has COLLPLANT HOLDI/S been receiving favorable news coverage?

Press coverage about CLGN stock has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. COLLPLANT HOLDI/S earned a coverage optimism score of 0.11 on Accern's scale. They also assigned news coverage about the company an impact score of 44.72 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are COLLPLANT HOLDI/S's major shareholders?

COLLPLANT HOLDI/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SAGI AMI (16.40%). View Institutional Ownership Trends for COLLPLANT HOLDI/S.

How do I buy shares of COLLPLANT HOLDI/S?

Shares of CLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is COLLPLANT HOLDI/S's stock price today?

One share of CLGN stock can currently be purchased for approximately $5.32.

How big of a company is COLLPLANT HOLDI/S?

COLLPLANT HOLDI/S has a market capitalization of $19.14 million and generates $480,000.00 in revenue each year. The company earns $-6,020,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. COLLPLANT HOLDI/S employs 29 workers across the globe.

How can I contact COLLPLANT HOLDI/S?

COLLPLANT HOLDI/S's mailing address is 3 SAPIR ST. WEIZMANN SCIENCE PARK P.O.B. 4132, NESS-ZIONA L3, 74140. The company can be reached via phone at 972-73-232-5600 or via email at [email protected]

MarketBeat Community Rating for COLLPLANT HOLDI/S (NASDAQ CLGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  12 (Vote Underperform)
Total Votes:  24
MarketBeat's community ratings are surveys of what our community members think about COLLPLANT HOLDI/S and other stocks. Vote "Outperform" if you believe CLGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.